Wnt signaling and breast cancer

Cancer Biol Ther. 2004 Jan;3(1):36-41. doi: 10.4161/cbt.3.1.561. Epub 2004 Jan 14.

Abstract

Secreted signaling factors of the Wnt protein family regulate many cellular processes, including cell fate decisions and cell proliferation, and aberrant Wnt signaling is associated with tumorigenesis. Many Wnt proteins act via a signaling pathway that results in stabilization of beta-catenin and consequent transcriptional activation of specific target genes. Mutations in beta-catenin or other Wnt pathway components, which result in beta-catenin accumulation, are found in a wide range of human cancers. In contrast, such mutations have been found only rarely in breast cancer. Nevertheless there is strong evidence of stabilization of beta-catenin protein in a majority of human breast tumors. Moreover, studies in mouse model systems clearly demonstrate that activated Wnt signaling leads to mammary tumorigenesis. This review summarizes the current evidence implicating Wnt/beta-catenin signaling in breast cancer and discusses several possible mechanisms by which the pathway may become activated.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / genetics*
  • Cytoskeletal Proteins / genetics
  • Female
  • Humans
  • Mammary Neoplasms, Experimental / physiopathology
  • Mice
  • Proto-Oncogene Proteins / genetics*
  • Signal Transduction
  • Trans-Activators / genetics
  • Wnt Proteins
  • beta Catenin

Substances

  • CTNNB1 protein, human
  • CTNNB1 protein, mouse
  • Cytoskeletal Proteins
  • Proto-Oncogene Proteins
  • Trans-Activators
  • Wnt Proteins
  • beta Catenin